Abstract The New York SGX Research Center for Structural Genomics (NYSGXRC) of the NIGMS Protein Structure Initiative (PSI) has applied its high-throughput Xray crystallographic structure determination platform to systematic studies of all human protein phosphatases and protein phosphatases from biomedically-relevant pathogens. To date, the NYSGXRC has determined structures of 21 distinct protein phosphatases: 14 from human, 2 from mouse, 2 from the pathogen Toxoplasma gondii, 1 from Trypanosoma brucei, the parasite responsible for African sleeping sickness, and 2 from the principal mosquito vector of malaria in Africa, Anopheles gambiae. These structures provide insights into both normal and pathophysiologic processes, including transcriptional regulation, regulation of major signaling pathways, neural development, and type 1 diabetes. In conjunction with the contributions of other international structural genomics consortia, these efforts promise to provide an unprecedented database and materials repository for structure-guided experimental and computational discovery of inhibitors for all classes of protein phosphatases.
Introduction
In 2000, the National Institute of General Medical Sciences (NIGMS) established the Protein Structure Initiative (PSI) with the goal to ''make the three-dimensional atomic-level structures of most proteins easily obtainable from knowledge of their corresponding DNA sequences'' to support biological and biomedical research (http://www.nigms.nih. gov/Initiatives/PSI.htm). This initial, pilot phase demonstrated the feasibility of the program, and Phase II of the program, PSI-II, was launched in 2005, supporting four large-scale production centers to continue high throughput structure determination efforts and six specialized centers to focus on specific bottlenecks such as membrane proteins and multi-component assemblies (Table 1) . More recently, these experimental efforts were supplemented by addition of two centers focused on enhancing comparative protein structure modeling, a PSI materials repository for centralized archiving and distribution of reagents, and a PSI knowledge base for data sharing (Table 1) .
Target selection represents a critical first step in the structural genomics pipeline, as it dictates the value of the ensuing structures. PSI-II employs a balanced target selection strategy that continues to emphasize the importance of large-scale structure determination and homology model generation, while exploiting the underlying infrastructure to address significant problems of biomedical relevance and to respond to the needs of the larger research community. About 70% of PSI-II efforts focus on the determination of structures with less than 30% amino acid sequence identity to an existing structure. This constraint is central to the overall goals of the PSI, as it is at approximately this level of sequence identity that homology modeling begins to fail due to difficulties in obtaining accurate primary sequence alignments. About 15% of PSI-II activities are committed to projects nominated by the greater scientific community, with the remaining 15% devoted to a biomedically relevant theme developed by each of the four large-scale centers.
NYSGXRC
The New York SGX Research Center for Structural Genomics (NYSGXRC; www.nysgxrc.org) has established a cost-effective, high-throughput X-ray crystallography platform for de novo determination of protein structures. NYSGXRC member organizations include SGX Pharmaceuticals, Inc. (www.sgxpharma.com), the Albert Einstein College of Medicine (www.aecom.yu.edu), Brookhaven National Laboratory (www.bnl.gov), Case Western Reserve University (www.cwru.edu), and the University of California at San Francisco (www.ucsf.edu). Together, scientists from these industrial and academic organizations support all aspects of PSI-II, including Family Classification and Target Selection, Generation of Protein for Biophysical Analyses, Sample Preparation for Structural Studies, Structure Determination, and Analyses and Dissemination of Results. Current NYSGXRC production metrics during the past 12 months (July 1st 2006-June 30th 2007) are as follows: generation of *2,060 target protein expression clones, *1,400 successful target protein purifications (all characterized by Matrix-Assisted Laser Desorption Ionization and ElectroSpray Ionization-Mass Spectrometry, and Analytical Gel Filtration), [ 360,000 initial crystallization experiments, [ 106,000 crystallization optimization experiments, *3,100 crystals harvested, [ 600 X-ray diffraction datasets recorded, and 158 structures deposited in the Protein Data Bank (PDB; www.pdb.org). We average *110 successful protein purifications per month and one structure deposition every 2-3 days. As mandated by PSI-II, approximately 15% of NYSGXRC resources are devoted to structure determination of its Biomedical Theme targets, protein phosphatases from human and various pathogens.
Motivation
Protein kinases and phosphatases act in counterpoint to control the phosphorylation states of proteins that regulate virtually every aspect of eukaryotic cell and molecular biology. Protein phosphorylation is a dynamic post-translational modification, which allows for processing and integration of extra-and intra-cellular signals. In vivo, protein kinases and phosphatases play antagonistic roles, controlling phosphorylation of specific protein substrates on tyrosine, serine, and threonine sidechains. These reversible phosphorylation events modulate protein function in various ways, including generation of ''docking sites'' that direct formation of multi-component protein assemblies, alteration of protein localization, modulation of protein stability, and regulation of enzymatic activity. Such molecular events modulate signal transduction pathways responsible for controlling cell cycle progression, differentiation, cell-cell and cell-substrate interactions, cell motility, the immune response, channel and transporter activities, gene transcription, mRNA translation, and basic metabolism. Aberrant regulation of protein phosphorylation results in significant perturbations of associated signaling pathways and is directly linked to a wide range of human diseases (see [1] for a recent review). PTEN, a phosphoinositide 3-phosphatase and the first member of the greater protein phosphatase family identified as a tumor suppressor, is inactivated by mutations in several neoplasias, including brain, breast, and prostate cancers. Cdc25A and cdc25B are potential oncogenes. Over-expression of PRL-1 and PRL-2 results in cellular transformation and PRL-3 is implicated as a metastasis factor in colorectal cancer. PTP1B is a primary target for therapeutic intervention in diabetes and obesity. CD45 is a target for graft rejection and autoimmunity. Mutations in EPM2A are responsible for a form of epilepsy, characterized by neurological degeneration and seizures.
The importance of protein phosphatases in mammalian physiology is underscored by strategies found in several pathogens, including Yersinia, Salmonella, and vaccinia viruses, in which pathogen encoded protein phosphatases disrupt host-signaling pathways and are essential for virulence. Systematic structural analysis of protein phosphatases provides an opportunity to make significant progress towards (i) understanding and treating the underlying mechanisms of human diseases, (ii) treating a wide range of opportunistic and infectious microorganisms, and (iii) generating reagents that permit experimentation to uncover new principles in cellular and molecular biology.
Our progress in this endeavor is shown in Fig. 1 , wherein the number of distinct phosphatases that have progressed to each experimental stage is shown. We have observed greater attrition for the pathogen phosphatases, due in part, we believe, to the fact that many of the sequences are gene predictions that have not been experimentally verified. To compare our work on the human versus pathogen proteins, of the 62 human/mouse proteins that we successfully purified, 15 yielded structures, whereas of the 55 pathogen phosphatases that we purified, only 5 have yielded structures thus far.
Families of protein phosphatases
The protein phosphatases encompass a range of structural families, mechanistic strategies and substrate specificities. The protein tyrosine phosphatases (PTPs) represent one of the largest families in the human genome with four distinct subfamilies, including (i) the classic PTPs that recognize phosphotyrosine residues (112 human proteins), which are further divided into several subclasses of receptor-like and intracellular cytosolic PTPs, (ii) the promiscuous dualspecificity phosphatases (DSPs), which recognize both phosphotyrosine and phosphoserine/phosphothreonine (33 human proteins) and include subfamiles of the phosphoinositide phosphatases (PTEN and myotubularin) and the mRNA 5 0 -triphosphatases (BVP and Mce1), (iii) the low molecular weight phosphatases that recognize phosphotyrosine residues, and (iv) the dual-specificity cdc25 phosphatases.
All members of the PTP family catalyze metal-independent dephosphorylation of phospho-amino acids, using a covalent phospho-cysteine intermediate to facilitate hydrolysis. The amino acid sequence hallmark of the PTP family is the HCXXGXXR(S/T) motif, which contains the cysteine nucleophile. A sequence alignment showing the family conservation in the 14 amino acids surrounding this motif is shown in Fig. 2a . It is remarkable that this active site feature represents the only amino acid sequence motif that is common to all PTP subfamily members.
The serine/threonine protein phosphatases are represented by two families which are distinguished by sequence homology and catalytic metal ion dependence. The PPP family members are Zn/Fe-dependent enzymes including PP1, PP2A, and PP2B (calcineurin) (*15 human proteins). The PPM or PP2C-like family members are Mn/ Mg-dependent enzymes (*16 human proteins). Despite sharing essentially no sequence similarity, members of [4, 5, 6, 7] . Dendrograms encompassing the recognized human phosphatases are shown in Fig. 2 (experimental 3D public domain structures are denoted therein with black circles). The active site motif (Fig. 2a) compared to a database of human phosphatases was used to construct the PTP/DSP tree ( Fig. 2b) , whereas a multiple sequence alignment of the catalytic domain sequences was used to characterize homology among the remaining phosphatases (e.g., PPM and PPP families; Fig. 2c ). There are over 225 mammalian phosphatase structures in the PDB, providing coverage with either an experimental structure or a highquality homology model for at least 64 human phosphatases (or *45% of the human phosphatome). Some human phosphatases have many structural representatives, like PTP1B with over 90 structures, whereas many others have only a single structure in the public domain. Unlike the protein kinases, which can be largely defined by a single Pfam entry, Pkinase (http://pfam.janelia.org/), the phosphatases are more diverse and require at least 12 Pfam entries to describe their varied families (see Table 2 for 7 distinct Pfam entries corresponding to NYSGXRC structures).
NYSGXRC target selection and progress
After the start of PSI-II, the NYSGXRC established a target list of human protein phosphatases for which there was no representative in the PDB. In addition, we selected structurally uncharacterized protein phosphatases from a number of pathogens for which sequence information was available. The coding sequences of most human phosphatases were cloned from cDNA libraries, some were purchased, and 16 were synthesized. All pathogen phosphatases were codon-optimized and synthesized (Codon Devices, Inc., Cambridge, MA). Work on the first group of 93 pathogen phosphatases began at the end of 2005 (Anopheles gambiae, Toxoplasma gondii, and Plasmodium falciparum). In early 2007, work on an additional *170 pathogen phosphatases was initiated, with targets selected from Candida albicans, Encephalitozoon cuniculi, Filobasidiella neoformans, Gibberella zeae, Cryptosporidium parvum, Fusarium graminearum, Trichomonas vaginalis, 
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Trypanosoma brucei, Aspergillus nidulans, Cryptococcus neoformans, Entamoeba histolytica, and Giardia lamblia. Two years after the start of PSI-II, we have produced viable expression vectors for 304 phosphatases, and purified crystallization-grade protein for 107 of these NYSGXRC Biomedical Theme targets. We have deposited 24 X-ray crystal structures of 21 distinct protein phosphatases into the PDB (see Table 2 for PDB IDs). Other structural biology groups and structural genomics centers have also determined significant numbers of protein phosphatase structures. Among the most productive are the SGC (Structural Genomics Consortium; http://www.sgc. utoronto.ca) and KRIBB (Korea Research Institute of Bioscience and Biotechnology; https://www.kribb.re.kr/ eng/index.asp), which have deposited structures of at least 19 and 7 distinct human phosphatases, respectively, within the past 2 years. There is relatively little overlap of newly deposited structures from competing consortia/ efforts.
To help minimize structure overlap among research groups, the NYSGXRC publishes its target list in the TargetDB database (http://targetdb.pdb.org/) on a weekly basis, which includes the experimental status of each target. We compare all of our targets against the contents of the PDB on a weekly basis and typically stop work on those that have been deposited by other groups. We publish experimental protocols for every trial of every target in the PepcDB database (http://pepcdb.pdb.org/); this includes not only detailed general protocols but also information about each clone (DNA sequence and predicted protein sequence, mutations, whether it has been codon-optimized, and small scale expression/solubility results), fermentation (media, volume, induction time and temperature, and resulting pellet weight), protein purification (yield, concentration), purified protein quality as judged by mass spectrometry (pass/fail, exact molecular weight), and crystallization conditions. We encourage this level of transparency for all structural genomics centers. Moreover, we make all of our reagents, such as expression clones, freely available. Sometime in 2008 we anticipate that all NYSGXRC expression clones will be distributed by the centralized PSI Material Repository, located within the Harvard Institute of Proteomics (HIP; http://www.hip. harvard.edu/).
Selected examples
The NYSGXRC Biomedical Theme project has yielded a number of important structures, which have already provided unique insights into a wide range of biological processes with direct relevance to human disease. Illustrative examples are highlighted below.
Protein tyrosine phosphatase sigma (PTPr)
The 21 human receptor protein tyrosine phosphatases share a common organization with extracellular ligand binding domains, a single transmembrane segment, and intracellular phosphatase catalytic domains that function in concert to regulate signaling through ligand-mediated tyrosine dephosphorylation. Twelve of these receptor PTPs possess two tandem-phosphatase domains with a catalytically active membrane proximal domain (D1) and a membrane distal domain (D2) that is thought to be inactive in most family members. PTPr belongs to the type 2A sub-family, which possess extracellular ligand binding domains composed of three immunoglobulin-like (Ig) domains and four to nine fibronectin type III-like (FNIII) domains [1, 8, 9] . Additional members of this sub-family include the human leukocyte common antigen-related PTP (LAR) and PTPdelta (PTPd) and the invertebrate orthologs Dlar and DPTP69D in Drosophila, PTP-3 in Caenorhabditis elegans, and HmLAR1 and HmLAR2 in Hirudo medicinalis. Expression of human receptor PTPs has been detected in all tissues examined, with the majority of PTPr and PTPd expression being detected in the brain [9] .
PTPr and other members of the type 2A sub-family play roles in regulating the central and peripheral nervous systems by providing and responding to cues for axon growth and guidance, synaptic function, and nerve repair. These complex functions appear to utilize cell-autonomous and non-cell-autonomous mechanisms, involving signals originating from both the cytoplasmic phosphatase domains and the ligand binding properties of the ectodomain [10] . Using brain lysates from PTPr-deficient mice, in combination with substrate trapping experiments, N-cadherin and b-catenin were identified as substrates of PTPr [10] . These findings led to a model of PTPr-regulated axon growth involving a cadherin/catenin-dependent pathway. In this model, PTPr directs the dephosphorylation of N-cadherin, which allows for the recruitment of b-catenin. In addition, PTPr-mediated dephosphorylatin of b-catenin allows for the subsequent linkage to the actin cytoskeleton, resulting in increased adhesion and reduced axon growth. In PTPrdeficient mice, the resulting hyperphosphorylation of Ncadherin and b-catenin prevents the linkage between the cytoskeleton and the plasma membrane, resulting in reduced adhesion and enhanced axon growth. Further support for this model is provided by observations that dorsal root ganglion axon growth is accelerated in PTPrdeficient mice. Of particular note, is the enhanced rate of nerve regeneration after trauma (e.g., crush or transection) in PTPr-deficient mice [11] . In addition to enhanced rates of regeneration, PTPr-deficient mice show an increased rate of errors in directional nerve growth, suggesting a role in both growth rates and the directional persistence or guidance of advancing neurons. The PTPr ectodomain has been implicated in non-cell-autonomous functions related to both optimal growth and guidance in regenerating neurons. These contributions to axon growth and regeneration make PTPr an interesting potential target for therapeutic intervention.
We have determined the structure of the tandem phosphatase domains of human PTPr (apoPTPr-D1-D2; PDB ID: 2FH7) (Fig. 3) . As observed in the structures of the LAR (type 2A) and CD45 (type 1/6) tandem phosphatases, the D1 and D2 domains of PTPr are very similar (rootmean-square-deviation or RMSD *1.0 Å ; this and all subsequent RMSD calculations are based on structurally equivalent Ca atoms) [12, 13] . The overall organization of the PTPr tandem phosphatase domains is very similar to that observed in CD45, LAR, and PTPc. This similarity is best appreciated by superimposing the D1 domain and examining the distribution of D2 positions (Fig. 4) . The relative domain organization is dictated by the residues that contribute to the D1-D2 interface, which are highly conserved among PTPr, LAR, and PTPc.
Defining the oligomeric state of the receptor PTPs is central to understanding ligand binding, activation, and underlying regulatory mechanisms. PTPr-D1-D2 is a monomer in the crystalline state and also behaves as a monomer in solution as judged by analytical gel filtration chromatography (unpublished data). It is remarkable that PTPa and CD45 have been reported to be negatively regulated by homodimerization [14, 15, 16] , although this remains an area of intense interest and some controversy [12, 13] . Recently, it has been suggested that PTPr forms homodimers in the cell and that dimerization is required for ligand binding [17] . The apparent discrepancy between these cell-based results and our biophysical studies may be resolved by demonstrations that dimerization depends, at least in part, on interactions involving the transmembrane segment [17] , which is absent from the D1-D2 construct used for our crystallographic and biophysical studies.
Both phosphatase domains in PTPr possess the characteristic CX 5 R catalytic site motif and are capable of binding the phosphate analog tungstate (refinement in progress, Fig. 3 ). However, as observed in most other receptor tyrosine phosphatases, the D2 domain of PTPr appears to be catalytically inactive [18] . All catalytically active D1 domains possess WPD and KNRY loops, which contain the catalytic acid (D) and participate in phosphotyrosine recognition, respectively. The lack of activity in the PTPr D2 domain is almost certainly due, at least in part, to the replacement of the WPD Asp with Glu and the KNRY Tyr with Leu (Fig. 5) . Similar changes are present in the catalytically defective D2 domains of LAR and PTPa [12, 19] , and restoration of the WPD and KNRY sequences in these domains results in a substantial enhancement of catalytic activity. The D2 domain is thought to play an important regulatory role as intermolecular and intramolecular binding interactions between D1 and D2 domains from the same and heterologous PTPs have been shown to modulate the catalytic activity of D1 [14, 18, 20, 21] . Insulinoma-associated protein 2 (IA-2)
Insulinoma-associated protein 2 (IA-2) is a member of the receptor-type protein tyrosine phosphatase family [22] . It is enriched in the secretory granules of neuroendocrine cells, including pancreatic islet b cells, peptidergic neurons, pituitary cells, and adrenal chromaffin cells [23] . The IA-2 protein is predicted to have a lumenal domain, a single transmembrane helix, and a cytoplasmic tail containing a protein tyrosine phosphatase-like domain. However, enzymatic activity has not been demonstrated for IA-2, and several substitutions within the phosphatase-like domain appear to be responsible for its apparent inactivity against substrates tested thus far [24] . Despite its apparent lack of phosphatase activity, the localization of IA-2 to the membrane of insulin secretory granules suggests that it may be involved in granule trafficking and/or maturation. Indeed, IA-2-deficient mice exhibit defects in glucose-stimulated insulin secretion [25] . IA-2 represents a major autoantigen in type 1 diabetes, with greater than 50% of patients demonstrating circulating antibodies to the protein [26, 27] . Processing of the *100-kD IA-2 protein involves proteolytic cleavage within the lumenal domain, resulting in a *64-kD mature form that is immunoprecipitated by insulin-dependent diabetes mellitus patient sera [28] . Autoantibodies to IA-2 can also be detected during the prediabetic period. Measurement of autoantibodies to IA-2, insulin, and glutamic acid decarboxylase (GAD65) enables prediction of type 1 diabetes in at-risk individuals, with the presence of two or more reactivities being highly predictive of future disease [29] . The humoral immune response in diabetes is primarily directed against conformational epitopes located within the cytoplasmic portion of the protein [26, 30, 31] . Distinct B cell epitopes are contained within polypeptide chain segments 605-620, 605-682, 687-979, and 777-937 [26] . As 
+ T cell responses to IA-2 peptides derived from these regions of the protein. CD8 + T cells specific for IA-2 have also recently been reported in type 1 diabetes patients [33] .
We have determined the structure of the IA-2 phosphatase-like domain (amino acids 681-979; PDB ID: 2I1Y), which reveals a classic protein tyrosine phosphatase architecture that is most similar to PTP1B (RMSD *1.4 Å ; Fig. 6 ). This structure also highlights residues responsible for the apparent lack of enzymatic activity. Although the CX 5 R sequence is present, several other critical residues are absent, including the catalytic acid (D) in the WPD loop and a major determinant (Y) in the phosphotyrosine-recognition loop. Lack of enzyme activity is thought to be essential for the biological function of IA-2, as it can heterodimerize with both PTPa and PTPe and down-regulate the activity of PTPa [34] . Our structure is particularly noteworthy for defining the relationship between the B cell and T cell epitopes, and thereby providing insights into the pathogenesis of type 1 diabetes. We suggest that T cell response development is facilitated by antibodies to IA-2. The presence of surface antibody would allow B cells to capture fragments of the protein and present IA-2-derived peptides on MHC molecules for recognition by T cells [35] . Antibody-bound protein fragments could also be directed to antigen-presenting cells via Fc receptors, a targeting that allows antigens to be efficiently processed and presented to T cells [36] . A bound antibody can also modulate processing of T cell determinants, suppressing the presentation of some epitopes and enhancing the generation of others, thus influencing the process of epitope spreading [37] [38] [39] .
Small C-terminal domain phosphatase 3
The small C-terminal domain phosphatases (SCP) comprise a family of Ser/Thr-specific phosphatases that play a central role in mRNA biogenesis via regulation of RNA polymerase II (RNAP II). RNAP II is a complex enzyme containing 12 protein subunits [40] , the largest of which bears a unique C-terminal domain (CTD) that is flexibly linked to a region of the macromolecular machine near the RNA exit pore. The CTD consists of multiple repeats of the consensus sequence Tyr1-Ser2-Pro3-Thr4-Ser5-Pro6-Ser7 [41] , with the number of repeats being species dependent (e.g., 26 are found in yeast versus 52 in human). Reversible phosphorylation of the CTD plays a crucial role in RNAP II progression through the transcription cycle, controlling both transcriptional initiation and elongation [42, 43] . The CTD phosphorylation status also affects RNA processing events, such as 5 0 -capping and 3 0 -processing [44] [45] [46] [47] . The CTD of RNAP II is predominantly phosphorylated at Ser2 and Ser5 within its heptapeptide repeats by members of the cyclin-dependent kinase (CDK) family (e.g., CDK7, CDK8, and CDK9) [48, 49] , while members of the SCP family work in opposition to restore the unphosphorylated Fig. 6 Comparison of the structures of IA-2 and PTP1B. Superposition of the structures of IA2 (green) and PTP1B (cyan), with active site residues shown as stick figures. Active site residues of IA2 and PTP1B bound to phosphotyrosine are magnified, highlighting differences responsible for the lack of catalytic activity of IA-2 state. It is remarkable that SCP family members also modulate the function of SMAD transcriptional regulators by dephosphorylating SMAD residues in the C-terminus and the linker region connecting two conserved domains [50, 51] .
As a consequence of their role in transcriptional regulation, SCP family phosphatases are linked to a wide range of physiological responses and pathologic processes. SCP3 has been identified as a tumor suppressor. The SCP3 gene is frequently ([90%) deleted or its expression is drastically reduced in lung and other major human carcinomas [52] . In contrast, a related family member, SCP2, was initially identified in a genomic region frequently amplified in sarcomas and brain tumors [53] . Members of the SCP family act as evolutionarily conserved transcriptional regulators that globally silence neuronal genes [54] . SCP2 interacts with the androgen receptor (AR) and appears to control promoter activity by RNAP II clearance during steroid-responsive transcriptional events [55] . FCP1, the first SCP related protein identified, interacts directly with HIV-1 Tat through its non-catalytic domain and is essential for TAT-mediated transcriptional transactivation [56] .
To date, the structures of three SCP family members have been determined, including the NYSGXRC structures of SCP2 (PDB ID: 2Q5E) and SCP3 (PDB ID: 2HHL). SCP3 is monomeric both in solution and the crystalline state, and shares high sequence identity (*83%) and significant structural similarity (RMSD *0.6 Å ) with both SCP1 (PDB ID: 2GHQ; [57, 58] ) and SCP2. These proteins belong to the haloacid dehalogenase (HAD) superfamily, which encompasses a large number of magnesium-dependent phosphohydrolases characterized by the presence of a conserved DXDX motif (Fig. 7) . This signature sequence contributes to the catalytic site, and is responsible for coordination of the catalytically essential magnesium cation, with the first aspartic acid serving as the nucleophile and phoshoryl acceptor [57] . Most HAD family members catalyze phosphoryl transfer reactions involving small molecule metabolites (e.g., phosphoserine). Structures of two HAD protein serine phosphatases from human (PDB ID: 1L8L, [59] ) and Methanococcus jannaschii (PDB ID: 1F5S; [60] ) have also been determined. Despite rather low sequence identity between the SCPs and small molecule phosphatases (14% between 2HHL and 1F5S; RMSD *2.7 Å ), they share significant similarities in overall topology and active site architecture (Fig. 8) .
SCP1, SCP2, and SCP3 are composed of a central fivestranded parallel b-sheet flanked by three a-helices on one side and a substantial loop-containing segment on the opposite face. An additional anti-parallel three-stranded bsheet is formed within the extended loop connecting bstrands 2 and 3 of the central b-sheet. In contrast, the M. jannaschii phosphoserine phosphatase (1F5S) contains both the core domain and a capping domain that impinges on the active site. In the case of the tetrameric Haemophilus influenzae deoxy-D-mannose-octulosonate 8-phosphatase (PDB IDs: 1K1E and 1J8D), an adjacent monomer packs on top of the core domain and serves as the ''cap'' (Fig. 8) .
As previously discussed by Allen, Dunaway-Mariano, and colleagues [4] , the overall architecture of these active sites appear to be related to the type of substrate recognized. For example, the phosphoserine phosphatases, which recognize small molecules, typically possess small catalytic sites that are relatively sequestered from solvent. Such sequestration is generally provided by the additional ''capping'' domain present in the structure, or by the formation of a higher order oligomeric species that occludes the catalytic site. In contrast, the SCP catalytic sites, which recognize CTD heptad repeats are larger and more accessible to solvent. This architectural variation may be of wider import. For example, in MDP-1, another putative HAD superfamily protein phosphatase that dephosphorylates phosphotyrosine [4] , the catalytic site also appears to be highly solvent accessible. Recently published work suggests that MDP-1 might recognize post translationallyencoded protein sugar phosphates, which would also require a substantially more accessible catalytic site [61] . This architectural type is also present in the phosphatase domain of T4 polynucleotide kinase, a HAD superfamily member that utilizes polynucleotide substrates [62] . It is remarkable that all of these polymer-specific HAD phosphatases recognize their substrates and perform catalysis at sites present at termini or linker regions. It, therefore, appears that a combination of catalytic site accessibility and substrate dynamics are required to support the biological activity of these polymer-specific phosphatases.
Chronophin
Chronophin is an example of the burgeoning family of ''moonlighting'' proteins [63, 64] , as it plays a central role in vitamin B6 metabolism and serves as a major regulator of the actin cytoskeleton [5] . This protein was first identified as pyridoxal phosphatase, which specifically dephosphorylates pyridoxal 5 0 -phosphate (PLP), the coenzymatically active form of vitamin B6 that participates in a remarkable range of enzymatic transformations [65] . PLP synthesis requires a flavin mononucleotide-dependent pyridoxine 5 0 -phosphate (PNP) oxidase and an ATPdependent pyridoxal kinase. Degradative pathways for PLP include the action of one or more pyridoxal phosphatases. The overall mechanism by which PLP levels are regulated is dauntingly complex and includes PLP biosynthetic and degradative pathways, PLP binding proteins, and proteins that regulate availability and/or transport of synthetic precursors. Given its central role in PLP metabolism, it is not surprising that the PLP phosphatase is expressed in all human tissues examined and is particularly abundant in brain, suggesting a specialized role in the CNS [66] .
More recently, Bokoch and colleagues demonstrated that chronophin plays a direct role in regulating the actin cytoskeleton [67] (Fig. 9) . Under physiological conditions, monomeric actin (G-actin) spontaneously polymerizes to form actin filaments (F-actin) with chemically and structurally distinct ends, termed barbed and pointed [68, 69] . Further assembly of F-actin into an array of higher order assemblies underlies all actin-based dynamic processes, including cell motility, vesicle movement, and cytokinesis. In vivo, actin polymerization is dominated by monomer addition to barbed ends, making barbed end generation a central focus in studies of dynamic actin-based processes [69, 70] . Cofilin is a 15 kD protein that severs the actin filament by disrupting the noncovalent bonds between monomers comprising the filament [71] . Filament severing increases the number of polymerization competent barbed ends, and results in increased rates of actin polymerization. Cofilin is also thought to be involved in depolymerization, because under certain conditions cofilin not only increases the number of filaments, but can also increase the rate of monomer dissociation from the newly created pointed ends [71] . Cofilin itself is regulated by a phosphorylation cycle: LIM kinase-mediated phosphorylation of Ser3 inactivates cofilin [72] while the action of the slingshot phosphatases return cofilin to the active state [71, 73] . Bokoch's work exploited a wide range of techniques to demonstrate chronophin specificity. siRNA knockdowns of chronophin activity (reduced phosphatase activity) increases phosphocofilin levels, while overexpression of chronophin decreases phosphocofilin levels. Decreased chronophin activity also results in stabilization of F-actin structures in vivo and causes massive defects in cell division [67] . The NYSGXRC structure of human chronophin (PDB ID: 2OYC) confirmed that this protein is indeed a member of the HAD family. It possesses a typical core domain that contains the catalytic signature sequence DXDX. There is also a very substantial capping domain that abuts the catalytic site (Fig. 10) . The structure of the PLP-bound form of the enzyme was obtained by substituting Mg 2+ (PDB ID: 2P27) with the catalytically inert Ca 2+ (PDB ID: 2P69). This substitution results in a change of metal ligation from six to seven coordinate via bidentate coordination of the catalytic aspartic acid (Asp25), which results in the near complete loss of activity (Fig. 11) . Our structure demonstrates that bound PLP is largely buried, with the phosphate being completely shielded from solvent (Figs. 10 and 12 ). Immediately after our first structure was deposited, three chronophin structures from Kang et al. [74] were made public via the PDB (PDB IDs: 2CFR, 2CFS, and 2CFT).
Demonstration of cofilin phosphatase activity is remarkable given the structural and functional features associated with all previously characterized polymer-specific HAD family phosphatases. As noted above, two members of the SCP family, MDP-1 and T4 polynucleotide kinase, all lack a capping domain, resulting in a relatively open and solvent-accessible catalytic site. In contrast, chronophin appears unique among the polymer-directed . The core domain is colored raspberry, the capping domain green, PLP is shown with stick representation and the Ca 2+ is shown as a green sphere. The catalytic site lies at the interface between the core and capping domains HAD phosphatases examined to date, because the presence of a substantial capping domain largely occludes the catalytic site (Figs. 12 and 13) . Analysis of our chronophin structure suggests that conformational reorganization of the core and capping domains is required to facilitate binding of the phosphorylated N-terminus of cofilin. The N-terminus of cofilin is unstructured in solution [75, 76] and, like the dynamic properties described above for other HAD-associated polymeric substrates, this behavior is almost certainly essential for it to gain access to the chronophin catalytic site. It, therefore, appears that the HAD family has evolved various mechanisms by which to perform chemistry on polymeric substrates. Availability of our structures and protein reagents provides the necessary foundation for a detailed study of chronophin function. These results will be particularly relevant to our fundamental understanding of cancer, as the phosphorylation status of cofilin is directly implicated in the actin-based mechanisms underlying invasion, intravasation, and metastasis of mammary tumors [77] .
Other phosphatases 4In addition to the human phosphatase structures described above, the NYSGXRC has determined and made publicly available X-ray structures from Toxoplasma gondii (PDB ID: 2ISN), mosquito (TAB1, PDB ID: 2IRM; and PPM1G, PDB ID: 2I0O), and Trypanosoma brucei (PDB ID: 2QJC), which will be described elsewhere.
More than a pretty picture
As highlighted by some of the examples described in detail above, a systematic structural characterization of the protein phosphatases provides significant mechanistic and functional insights. Notwithstanding these and other successes, we believe that full exploitation of the growing structural phosphatome database must include efforts to discover new therapeutic phosphatase inhibitors and generate reagents that allow for specific inhibition of signaling pathways in cell culture and whole animal model systems. There is much interest in the pharmaceutical and biotechnology industries in protein phosphatases as drug discovery targets, as evidenced by recent publications on PTP1B and related targets (reviewed in [78] ). Below, we briefly highlight two structure-based approaches from academe to the problem of discovering potent phosphatase inhibitors. 
Fragment condensation
The concept of inhibitor (or agonist) design via condensation of individual small molecule fragments known to bind proximally in the vicinity of a target protein active site has received growing attention over the past decade [79] . The simple rationale is that the geometrically appropriate covalent linkage of multiple low affinity fragments/functionalities will generate high affinity species. A rigorous thermodynamic treatment of this phenomenon was published by Jencks as early as 1981 [80] and demonstrated that the enhanced affinities of the final species is the consequence of both the additivity of the intrinsic binding energies (DG i ) of the individual fragments and the favorable entropic contribution associated with the linking of multiple fragments.
Fragment libraries are typically composed of 1,000-10,000 low molecular weight compounds representing a breadth of chemically diverse substructures that possess various chemical functional groups, which can facilitate either target binding or further chemical elaboration. Selection for solubility, lipophilicity, H-bonding donors/ acceptors, and known toxicity or ADME (Absorption, Distribution, Metabolism, and Excretion) properties are typical considerations in building the library.
Various approaches to fragment binding detection have been adopted, among them mass spectrometry [81] , NMR [82, 83] , crystallography [84, 85] and combinations therefrom [86, 87] . Special considerations for fragment based discovery using X-ray crystallography include the necessity for obtaining a well characterized crystal form of the target protein which diffracts well (d min \ 2.5 Å ), possesses a lattice amenable to soaking experiments (i.e., without occlusion of the target site), and is able to withstand exposure to modest quantities of organic solvents (e.g., ethanol and DMSO are popular solvents for chemical fragments). Initial crystal soaking experiments can be conducted on mixtures of the library to speed the initial screening with follow up soaks using individual fragments, where an individual component can not be conclusively identified from the resulting electron density maps. Judicious inclusion of heavy atom containing fragments (Br, I) can provide a significant anomalous scattering signal which can be used for simple deconvolution of fragment mixtures and defining fragment orientation. In addition, the use of Fig. 12 Chronophin capping domain. Superposition of chronophin (green) and SCP (CTD phosphatase) (red; PDB ID: 2HHL), which lacks a capping domain. The core domains share 11% sequence identity and superimpose with a DALI Z-score of 6.6 and an RMSD of *2.9 Å for 116 structurally equivalent Ca atoms Fig. 13 Inaccessibility of PLP in the Chronophin Catalytic Site. Surface representation of chronophin (blue) with bound ligand PLP (orange) in the same orientation as shown in Fig. 12 . The PLP is viewed on the edge and the phosphoryl group is completely buried from solvent halogen-substituted fragments provides a convenient synthetic ''handle'' for carbon-carbon bond formation. There are numerous examples in the literature of the success of this method, many coming from small biotechnology companies. Hartshorn et al. [88] have published a useful summary of the initial findings on five very different targets (p38 MAP kinase, CDK2, thrombin, ribonuclease A, and PTP1B). A detailed summary of the approach applied to spleen tyrosine kinase has been published by Blaney et al. [85] . The power of the method is highlighted by the following example for PTP1B, which represents the simplest possible approach to fragment screening with a screening library composed solely of phosphotyrosine.
An analysis of the substrate specificity of PTP1 (the rat ortholog of human PTP1B) revealed that this enzyme catalyzes hydrolysis of a wide variety of low molecular weight phosphate monoesters. One of these substrates (compound 1; Fig. 14) exhibits poor turnover (6.9 s -1 ) coupled with an extraordinarily low K m (16 lM) for a nonpeptidic species. The latter finding suggested that substrate might be binding tightly to the enzyme in a less than optimal fashion with respect to catalysis. Crystallographic analysis of compound 1 bound to a catalytically incompetent C215S mutant form of PTP1B revealed that the substrate can occupy one of two mutually exclusive binding modes: (1) a catalytically competent active site-bound form and (2) a nonproductive peripheral site-bound form (Fig. 15a) [89] . Furthermore, the less sterically demanding phosphotyrosine (''library of one'') was observed to simultaneously bind to both sites (Fig. 15b) . Although the active site is highly conserved among all PTPase family members, the peripheral position is not. This latter observation suggested that a bidentate ligand, capable of occupying both positions on the phosphatase, would not only display enhanced affinity but also enhanced selectivity for PTP1B. Based on these observations, a combinatorial library of 184 compounds was designed containing (1) a fixed phosphotyrosine moiety, (2) eight structurally diverse aromatic acids (terminal elements) to target the unique peripheral site, and (3) twenty-three structurally diverse ''linkers'' to tether the phosphotyrosine with the array of terminal elements [90] . Compound 2 was identified as the lead species from the library and the corresponding nonhydrolyzable difluorophosphonate (compound 3) was synthesized. Compound 3 exhibits high affinity (K i = 2.4 nM) and extraordinary selectivity (1,000-10,000-fold versus an array of phosphatases) for PTP1B. Analogs of this compound have recently been shown to serve as insulin sensitizers and mimetics in cell culture as well as appetite suppressors in animal models. These results are consistent with the role of PTP1B as a negative regulator of the insulin and leptin signaling pathways [91] . The structural biology that served as the source of inspiration to prepare the library of bidentate phosphatase inhibitors was based on the surprising finding that PTP1B can simultaneously bind two phosphotyrosine amino acid residues. However, nature had an additional surprise in store with the bidentate ligand compound 3, designed to coordinate to both the active and peripheral sites. Subsequent crystallographic analysis revealed that although compound 3 binds to the active site in the expected fashion, it does not coordinate to the predicted peripheral site (Fig. 16) . Instead, the bisphosphonate compound 3 coordinates in an unanticipated fashion to a completely different secondary site on the surface of the enzyme [92] . This secondary site, however, like the initially identified peripheral site, is not conserved among PTPase family members. The latter appears to provide the structural basis for the extraordinary selectivity displayed by compound 3 and its congeners for PTP1B. This serendipitous finding was the product of structure-guided library-screening and relied on access to purified protein samples; this underscores one of the under-appreciated and under-utilized deliverables of the Protein Structure Initiative: the expression clones and the purified proteins themselves.
Virtual inhibitor discovery
In silico virtual ligand screening (VS) uses computational approaches to identify small molecules ligands of target macromolecules. The process can be usefully divided into two stages, including docking and scoring. Docking utilizes a structure of the macromolecular target to calculate whether or not a particular compound can fit within a putative binding cleft (e.g., enzyme active site). Scoring methods estimate the free energy of binding for a particular ligand bound to the target in a particular pose, thereby permitting prioritization of predicted target-ligand complexes according to calculated binding energy.
Compound library selection plays an important role in VS. In principle, vast compound sets of diverse properties (including size, lipophilicity, and chemical substructure) are accessible to VS due to the availability of powerful computational resources. For example, Irwin and Shoichet have compiled a freely available database of *4.6 million commercially available compounds with multiple defined subsets, useful search functions, literature references, chemical similarity cross-references, vendor information, and atomic coordinates (http://blaster.docking.org/zinc/; [93] ). Moreover, the National Cancer Institute maintains a repository of over 140,000 compounds together with associated literature and structural information; 1,900 of these are arrayed on multi-well plates intended for use in ligand discovery (http://dtp.nci.nih.gov/index.html). For a review of the growing availability of chemical databases, see [94] .
While there certainly exists a benefit to having a source of the actual compound for follow-up in vitro studies, hypothetical small molecule compounds can also be generated in silico and serve as inputs for VS calculations. In practice, electronic compound libraries are processed [95] and filtered for a variety of properties (e.g., Lipinski's rules) either prior to VS ('forward filtering') in order to generate a smaller test set on which more thorough calculations can be undertaken, or after VS ('backward filtering') to eliminate excessive downstream chemistry on candidates with poor chemical properties [96] . Moreover, in contrast to fragment approaches (see above) for which very small molecules are observed to bind specifically, albeit sometimes quite weakly, to the target protein, VS methods encounter difficulty placing fragment molecules unless the binding landscape is limited to a manageably small area of the target protein surface. Thus, for VS, library components are usually larger and somewhat more elaborated compounds. Selection of an appropriate ''druggable'' macromolecular target is also a critical concern. The availability of high resolution structural data not only supports VS in general, but allows for the objective assessment, selection, and accurate boundary definition of the protein surface site to be interrogated (e.g., [97, 98] ).
A VS campaign against a phosphatase target for which no known non-phosphate based inhibitor was known has been published recently [99] . The authors selected PP2Ca as a target due to its importance in cell cycle and stress response pathways and the availability of a crystal structure (PDB ID: 1A6Q; [100] ). While inspection of the enzyme binding site revealed three putative binding pockets, PP2Ca represents a more difficult case for VS due to the presence of two bound metal ions coordinated by six waters leading to ambiguity concerning the relevant target structure. Using AutoDock 3.0 [101] , the authors ran docking and scoring calculations against controls (pSer, pThr, and pNPP docked nicely with phosphate groups overlaying a free phosphate observed in the structure) and the NCI Diversity Set (1,990 compounds). This initial screening exercise was followed by a chemical similarity search of the Open NCI Database (currently over 250,000 small molecule structures) resulting in a second generation library, which was also docked against PP2Ca and the resulting hits scored. Additional docking calculations were run on the most attractive looking hits against the apo form of the protein (deleting metals and waters) and all 64 possible permutations of water deletions (while still retaining the active site metals). Perhaps as an indication of binding to pockets surrounding the metals, there was some agreement among the runs with metal/water deletions when compared to the original run. Post-scoring filtering for solubility (compounds with log P \ 6 were kept) yielded some leads, which were then requested from the NCI and run in an inhibition assay against PP2Ca and a panel of three additional Ser/Thr phosphatases. Additional runs testing for inhibition due to aggregation by varying enzyme concentration or adding detergent were conducted. Remarkably, at compound concentrations of 100 lM, many of VS hits demonstrated robust inhibitory activity; one compound (109268) showed *80% inhibition of PP2Ca and reasonable selectivity for PP2Ca and PP1 over PP2A and PP2B (80% versus 40% inhibition) with no appreciable aggregation effects. No further elaboration of these leads was described.
In light of this result, it is of considerable interest that the NYSGXRC has recently determined the structure of a human PP2Cb (PPM1B) fragment (PDB ID: 2P8E) and the Toxoplamsa gondii ortholog of PPM2C (PDB ID: 2I44; herein referred to as PP2Ctg). The structures of PP2Ca and PP2Cb are nearly identical (RMSD *0.8 Å ; 80% sequence identity), although the PP2Cb expression construct does not encompass *90 C-terminal residues, which form a small helical subdomain distal to the active site in PP2Ca. The structure of Ser/Thr phosphatase PP2Ctg (Fig. 17) compares well with human PP2Ca [100] and human PP2Cb structures. RMSDs calculated by comparing the structure of PP2Ctg to hPP2Ca and hPP2Cb are *1.9 Å (23% sequence identity) and *1.8 Å (25% sequence identity), respectively (Fig. 18) . The four-layered abba architecture, the number of strands, and the location and coordination of the di-metal center are conserved among these structures. Although the core catalytic domain structure is conserved, there are significant differences between the human and the T. gondii enzymes. The helices in PP2Ctg are longer than those found in the human enzyme structures in one of the a-layers and PP2Ctg lacks the C-terminal 3 helices present in the human sequences. Importantly, in the vicinity of the active site, PP2Ctg possesses two insertions (residues 207-213 and 218-232 of PP2Ctg) forming an a-helix and a b-sheet, which are not found in the human PP2Cs (Figs. 18 and 19a ). Another significant difference affecting the nature of the active site arises from the disposition of the N-terminus. In the human structures, the N-terminus is close to the active site and forms an additional strand along one side of the betasandwich (Fig. 19b) , whereas in PP2Ctg, the N-terminus folds down away from the metals and forms contacts on either side of the sheets. Several other residues found within the vicinity of the active site and identified as potentially important for ligand binding to human PP2Ca [99] are not conserved: V34?K, E35?H, H62?T, A63?V, and R186?F (PP2Ca numbering). This sequence/structure divergence gives rise to significant variation in the active sites of human versus T. gondii PP2Cs (Fig. 19a, b) and may provide the basis for discovery and development of parasite selective phosphatase inhibitors.
Conclusion
The impact of various structural genomics efforts on our structural and functional understanding of the human protein phosphatases and protein phosphatases from a wide range of biomedically-relevant pathogens is already apparent. Current coverage of the human protein phosphatome is *45%, with the promise of many more structures to come within the next few years. These data will provide insights into both normal and pathophysiologic processes, including transcriptional regulation, regulation of major signaling pathways, neural development, and type 1 diabetes. They will also help to stimulate and support discovery of specific small molecule inhibitors of phosphatases, for use both in biomedical research and in various clinical settings.
